Tuesday, April 3, 2018
In 2017, Biogen launched Spinraza, an innovative medicine for the treatment of Spinal Muscular Atrophy (SMA), a fatal disease of children. Spinraza was the first of a revolutionary class of drugs termed antisense therapeutics. In 2018, Spinraza is expected to generate over $1.5 billion in revenues for Biogen and their partner, Ionis Pharmaceuticals. Bentley alumnus Lance Colwell ’92, former Vice President for the U.S. Rare Disease Group at Biogen, and Wildon Farwell, Senior Medical Director of Clinical Development at Biogen, discussed the commercial launch of the revolutionary new product, Spinraza.